TY - JOUR AU - Metro, Giulio PY - 2018 TI - EGFR targeted therapy for lung cancer: are we almost there? JF - Translational Lung Cancer Research; Vol 7, Supplement 2 (April 23, 2018): Translational Lung Cancer Research Y2 - 2018 KW - N2 - In the era of precision medicine, predictive biomarkers have revolutionized the therapeutic approach to advanced non-small cell lung cancer (NSCLC) (1). So far, sensitizing epidermal growth factor ( EGFR ) mutations (exon 19 deletion or exon 21 L858R) and anaplastic lymphoma kinase ( ALK ) rearrangements are among the best described targetable alterations, against which highly effective small molecules tyrosine-kinase inhibitors (TKIs) have been developed. UR - https://tlcr.amegroups.org/article/view/19927